How safe is safe: New human immunodeficiency virus Type 1 variants missed by nucleic acid testing

Transfusion

Volumn 53, Issue 10 PART 2, 2013, Pages 2422-2430

  Müller, Benjamin ^a,b,c   Nübling, C Micha ^a,b,c   Kress, Julia ^a,b,c   Roth, W Kurt ^a,b,c   De Zolt, Silke ^a,b,c   Pichl, Lutz ^a,b,c  

^a DRK Blutspendedienst NRW gGmbH   (Germany)

^b PAUL EHRLICH INSTITUT   (Germany)

^c GFE Blut mbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; BLOOD; BLOOD DONOR; BLOOD SAFETY; CASE REPORT; DIAGNOSTIC ERROR; DISEASE TRANSMISSION; FEMALE; GENETIC VARIABILITY; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISOLATION AND PURIFICATION; LABORATORY DIAGNOSIS; MALE; MASS SCREENING; METHODOLOGY; MIDDLE AGED; MOLECULAR GENETICS; NUCLEIC ACID AMPLIFICATION; NUCLEOTIDE SEQUENCE; SEROLOGY; STANDARD; STATISTICS; HIV INFECTIONS; PROCEDURES; STANDARDS; STATISTICS AND NUMERICAL DATA; TRANSMISSION;

ADOLESCENT; ADULT; BASE SEQUENCE; BLOOD DONORS; BLOOD SAFETY; DIAGNOSTIC ERRORS; FALSE NEGATIVE REACTIONS; FEMALE; GENETIC VARIATION; HIV INFECTIONS; HIV-1; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; MOLECULAR SEQUENCE DATA; NUCLEIC ACID AMPLIFICATION TECHNIQUES; SEROLOGIC TESTS;

EID: 84891678640     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12298     Document Type: Article

References (31)

1. Seedat J, Marcus U. HIV-infektionen und AIDSerkrankungen in Deutschland. Epidemiol Bull 2012;28:256-74.
2. Offergeld R, Ritter S, Hamouda O. [HIV, HCV, HBV and syphilis surveillance among blood donors in Germany 2008-2010]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2012;55:907-13.
3. Cohen MS, Hellmann N, Levy JA, DeCock K, Lange J. The spread, treatment, and prevention of HIV-1: evolution of a global pandemic. J Clin Invest 2008;118:1244-54.
4. Chudy M, Weber-Schehl M, Pichl L, Jork C, Kress J, Heiden M, Funk MB, Nübling CM. Blood screening nucleic acid amplification tests for human immunodeficiency virus Type 1 may require two different amplification targets. Transfusion 2012;52:431-9.
5. Roth WK, Busch MP, Schuller A, Ismay S, Cheng A, Seed CR, Jungbauer C, Minsk PM, Sondag-Thull D, Wendel S, Levi JE, Fearon M, Delage G, Xie Y, Jukic I, Turek P, Ullum H, Tefanova V, Tilk M, Reimal R, Castren J, Naukkarinen M, Assal A, Jork C, Reesink HW et al. International survey on NAT testing of blood donations: expanding implementation and yield from 1999 to 2009. Vox Sang 2012;102:82-90.
6. Roth WK, Weber M, Buhr S, Drosten C, Weichert W, Sireis W, Hedges D, Seifried E. Yield of HCV and HIV-1 NAT after screening of 3.6 million blood donations in central Europe. Transfusion 2002;42:862-8.
7. Roth WK, Weber M, Petersen D, Drosten C, Buhr S, Sireis W, Weichert W, Hedges D, Seifried E. NAT for HBV and anti-HBc testing increase blood safety. Transfusion 2002; 42:869-75.
8. Roth WK, Weber M, Seifried E. Feasibility and efficacy of routine PCR screening of blood donations for hepatitis C virus, hepatitis B virus, and HIV-1 in a blood-bank setting. Lancet 1999;353:359-63.
9. Schmidt M, Korn K, Nübling CM, Chudy M, Kress J, Horst HA, Geusendam G, Hennig H, Sireis W, Rabenau HF, Doerr HW, Berger A, Hourfar MK, Gubbe K, Karl A, Fickenscher H, Tischer BK, Babiel R, Seifried E, Gurtler L. First transmission of human immunodeficiency virus Type 1 by a cellular blood product after mandatory nucleic acid screening in Germany. Transfusion 2009;49:1836-44.
10. Paul-Ehrlich-Institut. Bekanntmachung über die Ergebnisse des Stufenplanverfahrens zur Verminderung des Risikos von Hepatitis B-, Hepatitis C-und HIV-Infektionen bei Empfängern von Erythrozytenkonzentraten (BAnz. Nr. 63 vom 04.04.97, S. 4477) vom 25. Februar 1998. Bundesanzeiger 1998;53:12269-70.
11. Paul-Ehrlich-Institut. Verminderung des Risikos von HIV-IInfektionen durch zelluläre Blutprodukte und gefrorenes Frischplasma. Anordnung der Testung auf HIV-I-RNA mit Nukleinsäure-Amplifikationstechniken. Bundesanzeiger 2003;103:3835-6.
12. Hourfar MK, Jork C, Schottstedt V, Weber-Schehl M, Brixner V, Busch MP, Geusendam G, Gubbe K, Mahnhardt C, Mayr-Wohlfart U, Pichl L, Roth WK, Schmidt M, Seifried E, Wright DJ; German Red Cross NATSG. Experience of German Red Cross blood donor services with nucleic acid testing: results of screening more than 30 million blood donations for human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus. Transfusion 2008; 48:1558-66.
13. Salazar-Gonzalez JF, Bailes E, Pham KT, Salazar MG, Guffey MB, Keele BF, Derdeyn CA, Farmer P, Hunter E, Allen S, Manigart O, Mulenga J, Anderson JA, Swanstrom R, Haynes BF, Athreya GS, Korber BT, Sharp PM, Shaw GM, Hahn BH. Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. J Virol 2008; 82:3952-70.
14. Paul-Ehrlich-Institut. Anordnung von Maßnahmen zur Risikominimierung beim Einsatz von HIV-1 NATTestsystemen (BAnz AT 12.09.2012 B6). Bundesanzeiger 2012.
15. Alter HJ, Stramer SL, Dodd RY. Emerging infectious diseases that threaten the blood supply. Semin Hematol 2007; 44:32-41.
16. Tapper ML. Emerging viral diseases and infectious disease risks. Haemophilia 2006;12(Suppl 1):3-7; discussion 26-8.
17. Van der Bij AK, Coutinho RA, Van der Poel CL. Surveillance of risk profiles among new and repeat blood donors with transfusion-transmissible infections from 1995 through 2003 in the Netherlands. Transfusion 2006;46:1729-36.
18. Kwon JA, Yoon SY, Lee CK, Lim CS, Lee KN, Sung HJ, Brennan CA, Devare SG. Performance evaluation of three automated human immunodeficiency virus antigen-antibody combination immunoassays. J Virol Methods 2006;133:20-6.
19. Ly TD, Laperche S, Brennan C, Vallari A, Ebel A, Hunt J, Martin L, Daghfal D, Schochetman G, Devare S. Evaluation of the sensitivity and specificity of six HIV combined p24 antigen and antibody assays. J Virol Methods 2004;122:185-94.
20. Sickinger E, Stieler M, Kaufman B, Kapprell HP, West D, Sandridge A, Devare S, Schochetman G, Hunt JC, Daghfal D; Ax SYMCSG. Multicenter evaluation of a new, automated enzyme-linked immunoassay for detection of human immunodeficiency virus-specific antibodies and antigen. J Clin Microbiol 2004;42:21-9.
21. Assal A, Barlet V, Deschaseaux M, Dupont I, Gallian P, Guitton C, Morel P, van Drimmelen H, David B, Lelie N, De Micco P. Sensitivity of two hepatitis B virus, hepatitis C virus (HCV), and human immunodeficiency virus (HIV) nucleic acid test systems relative to hepatitis B surface antigen, anti-HCV, anti-HIV, and p24/anti-HIV combination assays in seroconversion panels. Transfusion 2009;49: 301-10.
22. Busch MR. Evolving approaches to estimate risks of transfusion- transmitted viral infections: incidence-window period model after ten years. Dev Biol (Basel) 2007;127:87-112.
23. Fiebig EW, Wright DJ, Rawal BD, Garrett PE, Schumacher RT, Peddada L, Heldebrant C, Smith R, Conrad A, Kleinman SH, Busch MP. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS 2003; 17:1871-9.
24. Vermeulen M, Busch MP, Lelie N, Sykes W, Swaneveleder R, Le Roux M, Gaggia L, Reddy R. Observed yield and projected residual risk using HIV individual donation (ID)-NAT, minipool (MP)-NAT or HIV p24 antigen (p24 Ag) screening in South Africa. Vox Sang 2008;95(Suppl 1):55-6.
25. Christopherson C, Sninsky J, Kwok S. The effects of internal primer-template mismatches on RT-PCR: HIV-1 model studies. Nucleic Acids Res 1997;25:654-8.
26. Stadhouders R, Pas SD, Anber J, Voermans J, Mes TH, Schutten M. The effect of primer-template mismatches on the detection and quantification of nucleic acids using the 5' nuclease assay. J Mol Diagn 2010;12:109-17.
27. Vandamme AM, Van Laethem K, Schmit JC, VanWijngaerden E, Reynders M, Debyser Z, Witvrouw M, Van Ranst M, De Clercq E, Desmyter J. Long-term stability of human immunodeficiency virus viral load and infectivity in whole blood. Eur J Clin Invest 1999;29:445-52.
28. Drosten C, Panning M, Drexler JF, Hansel F, Pedroso C, Yeats J, de Souza Luna LK, Samuel M, Liedigk B, Lippert U, Sturmer M, Doerr HW, Brites C, Preiser W. Ultrasensitive monitoring of HIV-1 viral load by a low-cost real-time reverse transcription-PCR assay with internal control for the 5' long terminal repeat domain. Clin Chem 2006;52: 1258-66.
29. Kleinman SH, Lelie N, Busch MP. Infectivity of human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus and risk of transmission by transfusion. Transfusion 2009;49:2454-89.
30. Swanson P, Huang S, Abravaya K, de Mendoza C, Soriano V, Devare SG, Hackett J Jr. Evaluation of performance across the dynamic range of the Abbott RealTime HIV-1 assay as compared to VERSANT HIV-1 RNA 3.0 and AMPLICOR HIV-1 MONITOR v1.5 using serial dilutions of 39 group M and O viruses. J Virol Methods 2007;141: 49-57.
31. Swanson P, Huang S, Holzmayer V, Bodelle P, Yamaguchi J, Brennan C, Badaro R, Brites C, Abravaya K, Devare SG, Hackett J Jr. Performance of the automated Abbott realtime HIV-1 assay on a genetically diverse panel of specimens from Brazil. J Virol Methods 2006;134: 237-43.